[{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Eris Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Everolimus","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Biocon Biologics \/ Eris Lifesciences","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Eris Lifesciences"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Trastuzumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocon Biologics \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Sandoz"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Eris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Metoprolol Succinate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Biocon Biologics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.14999999999999999,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Biocon Biologics \/ Eris Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Eris Pharmaceuticals"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Biocon Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biocon Biologics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"14","companyTruncated":"Biocon Biologics \/ Johnson & Johnson Innovative Medicine"}]

Find Clinical Drug Pipeline Developments & Deals by Biocon Biologics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The agreement aims to commercialize its Bmab 1200, a proposed biosimilar to Stelara and a monoclonal antibody medication, in Europe, the United Kingdom (UK), Canada, and Japan.

                          Brand Name : Bmab 1200

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 29, 2024

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Johnson & Johnson Innovative Medicine

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Yesafili (aflibercept) is a PGF & VEGF-A inhibitor, its single-dose vial formulation is approved for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema.

                          Brand Name : Yesafili

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 21, 2024

                          Lead Product(s) : Aflibercept

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The collaboration aims to support the Biocon for the commercialization of ACTIBLOK IPR 25 (metoprolol succinate). It is an approved product indicated for hypertension and angina pectoris.

                          Brand Name : ACTIBLOK IPR 25

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 13, 2024

                          Lead Product(s) : Metoprolol Succinate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Eris Pharmaceuticals

                          Deal Size : $150.0 million

                          Deal Type : Collaboration

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The partnership seeks to enhance the commercialization efforts of Ogivri (trastuzumab), an FDA-approved biosimilar utilized in patients diagnosed with breast cancer or metastatic stomach cancer.

                          Brand Name : Ogivri

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 10, 2024

                          Lead Product(s) : Trastuzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Sandoz B2B

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Through the divestment, Eris gains Biocon's Dermatology and Nephrology branded formulations business units in India that mostly comprised of its legacy small molecules’ brands, including Advacan (everolimus), an anti-cancer medicine.

                          Brand Name : Advacan

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 09, 2023

                          Lead Product(s) : Everolimus

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Eris Lifesciences

                          Deal Size : $43.8 million

                          Deal Type : Divestment

                          blank